PMID- 19061426
OWN - NLM
STAT- MEDLINE
DCOM- 20090416
LR  - 20090309
IS  - 1937-3341 (Print)
IS  - 1937-3341 (Linking)
VI  - 15
IP  - 3
DP  - 2009 Mar
TI  - Endothelial precursor cells home to a vascularized tissue engineering chamber by 
      application of the angiogenic chemokine CXCL12.
PG  - 655-64
LID - 10.1089/ten.tea.2007.0438 [doi]
AB  - Tissue engineering of vascularized constructs has great utility in reconstructive 
      surgery. While we have been successful in generating vascularized 
      granulation-like tissue and adipose tissue in an in vivo tissue engineering 
      chamber, production of other differentiated tissues in a stable construct remains 
      a challenge. One approach is to utilize potent differentiation factors, which can 
      influence the base tissue. Endothelial precursor cells (EPCs) have the ability to 
      both carry differentiation factors and home to developing vasculature. In this 
      study, proof-of-principle experiments demonstrate that such cells can be 
      recruited from the circulation into an in vivo tissue engineering chamber. CXC 
      chemokine ligand 12 (CXCL12)/stromal cell-derived factor 1 was infused into the 
      chamber through Alzet osmotic pumps and chamber cannulation between days 0 and 7, 
      and facilitated recruitment of systemically inoculated exogenous human EPCs 
      injected on day 6. CXCL12 infusion resulted in an eightfold increase in EPC 
      recruitment, 2 (p = 0.03) and 7 days postinfusion (p = 0.008). Delivery of 
      chemotactic/proliferation and/or differentiation factors and appropriately timed 
      introduction of effective cells may allow us to better exploit the regenerative 
      potential of the established chamber construct.
FAU - Simcock, Jeremy W
AU  - Simcock JW
AD  - Bernard O'Brien Institute of Microsurgery and University of Melbourne Department 
      of Surgery at St Vincent's Hospital, Melbourne, Australia.
FAU - Penington, Anthony J
AU  - Penington AJ
FAU - Morrison, Wayne A
AU  - Morrison WA
FAU - Thompson, Erik W
AU  - Thompson EW
FAU - Mitchell, Geraldine M
AU  - Mitchell GM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Tissue Eng Part A
JT  - Tissue engineering. Part A
JID - 101466659
RN  - 0 (Angiogenesis Inducing Agents)
RN  - 0 (Antigens, CD34)
RN  - 0 (Chemokine CXCL1)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (RNA, Messenger)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Angiogenesis Inducing Agents/*pharmacology
MH  - Animals
MH  - Antigens, CD34/metabolism
MH  - Cell Count
MH  - Cell Movement/*drug effects
MH  - Chemokine CXCL1/genetics/metabolism
MH  - Chemokine CXCL12/genetics/metabolism/*pharmacology
MH  - Endothelial Cells/*cytology/drug effects
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Immunohistochemistry
MH  - Leukocytes/cytology
MH  - Neovascularization, Physiologic/*drug effects
MH  - RNA, Messenger/genetics/metabolism
MH  - Rats
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Stem Cells/*cytology/drug effects
MH  - *Tissue Engineering
MH  - Vascular Endothelial Growth Factor A/genetics/metabolism
MH  - Vascular Patency/drug effects
EDAT- 2008/12/09 09:00
MHDA- 2009/04/17 09:00
CRDT- 2008/12/09 09:00
PHST- 2008/12/09 09:00 [pubmed]
PHST- 2009/04/17 09:00 [medline]
PHST- 2008/12/09 09:00 [entrez]
AID - 10.1089/ten.tea.2007.0438 [doi]
PST - ppublish
SO  - Tissue Eng Part A. 2009 Mar;15(3):655-64. doi: 10.1089/ten.tea.2007.0438.